TY - JOUR
T1 - Two cases in which eribulin mesylate was effective for taxane-resistant advanced breast cancer
AU - Adachi, Keita
AU - Suzuki, Shuhei
AU - Kubota, Hitomi
AU - Hara, Yukiko
AU - Fujiwara, Asako
AU - Waga, Eiko
AU - Hirano, Tomohiro
AU - Enomoto, Katsuhisa
AU - Sakurai, Kenichi
AU - Makishima, Makoto
AU - Koshinaga, Tsugumichi
PY - 2017/10
Y1 - 2017/10
N2 - We experienced 2 cases in which eribulin mesylate was effective for taxane-resistant advanced breast cancer. Case 1: A 65-year-old woman was diagnosed with advanced breast cancer (T4cN2aM0, stage MB) and treated with chemotherapy (nab-paclitaxel). Bone metastasis was observed; then, she sequentially received epirubicin and cyclophosphamide, nab-paclitaxel, and bevacizumab and paclitaxel. However, lung metastases appeared, and we changed the regimen to eribulin mesylate. We administered 11 courses of eribulin mesylate before bone marrow metastasis appeared. Eribulin mesylate was effective for more than 1 year. Case 2: A 77-year-old woman was diagnosed with advanced breast cancer (T4bN3cM1, stage IV), and liver and pleural metastasis were observed during an examination at the first visit. Four courses of nab-paclitaxel were administered, but because of the increase in pleural effusion, we changed the regimen to eribulin mesylate. Thirteen courses of eribulin mesylate were administered before the disease progressed. The progression-free survival was 9.53 months. Through the 2 cases in which eribulin mesylate was effective for taxane-resistant advanced breast cancer, the effect of eribulin mesylate compared to taxane was clinically inferred.
AB - We experienced 2 cases in which eribulin mesylate was effective for taxane-resistant advanced breast cancer. Case 1: A 65-year-old woman was diagnosed with advanced breast cancer (T4cN2aM0, stage MB) and treated with chemotherapy (nab-paclitaxel). Bone metastasis was observed; then, she sequentially received epirubicin and cyclophosphamide, nab-paclitaxel, and bevacizumab and paclitaxel. However, lung metastases appeared, and we changed the regimen to eribulin mesylate. We administered 11 courses of eribulin mesylate before bone marrow metastasis appeared. Eribulin mesylate was effective for more than 1 year. Case 2: A 77-year-old woman was diagnosed with advanced breast cancer (T4bN3cM1, stage IV), and liver and pleural metastasis were observed during an examination at the first visit. Four courses of nab-paclitaxel were administered, but because of the increase in pleural effusion, we changed the regimen to eribulin mesylate. Thirteen courses of eribulin mesylate were administered before the disease progressed. The progression-free survival was 9.53 months. Through the 2 cases in which eribulin mesylate was effective for taxane-resistant advanced breast cancer, the effect of eribulin mesylate compared to taxane was clinically inferred.
KW - Breast cancer
KW - Chemotherapy
KW - Eribulin mesylate
UR - http://www.scopus.com/inward/record.url?scp=85040524852&partnerID=8YFLogxK
M3 - Review article
C2 - 29066702
AN - SCOPUS:85040524852
SN - 0385-0684
VL - 44
SP - 938
EP - 940
JO - Japanese Journal of Cancer and Chemotherapy
JF - Japanese Journal of Cancer and Chemotherapy
IS - 10
ER -
